MEI Pharma Inc (MEIP)

1.58
0.00 (0.00)
NASDAQ : Health Care
Prev Close 1.58
Open 1.60
Day Low/High 1.57 / 1.65
52 Wk Low/High 0.87 / 2.12
Volume 685.98K
Avg Volume 234.60K
Exchange NASDAQ
Shares Outstanding 36.77M
Market Cap 56.63M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MEI Pharma To Present At Wedbush PacGrow Healthcare Conference

MEI Pharma To Present At Wedbush PacGrow Healthcare Conference

Live Webcast from New York on August 16th

Helsinn Group And MEI Pharma Enter Strategic Agreement For The Development And Commercialization Of Pracinostat For The Treatment Of Acute Myeloid Leukemia And Other Hematologic Diseases

Helsinn Group And MEI Pharma Enter Strategic Agreement For The Development And Commercialization Of Pracinostat For The Treatment Of Acute Myeloid Leukemia And Other Hematologic Diseases

MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales

Interesting MEIP Call Options For December 16th

Interesting MEIP Call Options For December 16th

Investors in MEI Pharma Inc saw new options begin trading this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 136 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MEI Pharma Announces New Clinical Data From First-in-Human Study Of ME-401, A Next Generation Oral PI3K Delta Inhibitor

MEI Pharma Announces New Clinical Data From First-in-Human Study Of ME-401, A Next Generation Oral PI3K Delta Inhibitor

Data Presented at AACR Show Excellent PK/PD, Potential for Improved Therapeutic Window

MEI Pharma To Present At Needham Healthcare Conference

MEI Pharma To Present At Needham Healthcare Conference

Live Webcast from New York on April 12th

MEI Pharma To Present At BIO CEO & Investor Conference

MEI Pharma To Present At BIO CEO & Investor Conference

Live Webcast from New York on February 8th

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) stock is surging in early-morning trading on Monday, after the oncology company announced positive results from its leukemia treatment's Phase II trial.

MEI Pharma To Host Annual Meeting Of Stockholders

MEI Pharma To Host Annual Meeting Of Stockholders

Live Webcast from New York on December 3rd

MEI Pharma To Present At Stifel Healthcare Conference

MEI Pharma To Present At Stifel Healthcare Conference

Live Webcast from New York on November 18th

MEI Pharma Highlights New Data From Phase II Clinical Studies Of Pracinostat In Acute Myeloid Leukemia And Myelodysplastic Syndrome

MEI Pharma Highlights New Data From Phase II Clinical Studies Of Pracinostat In Acute Myeloid Leukemia And Myelodysplastic Syndrome

American Society of Hematology Annual Meeting Abstracts Now Available

MEI Pharma To Present At 14th Annual BIO Investor Forum

MEI Pharma To Present At 14th Annual BIO Investor Forum

Live Webcast from San Francisco on October 21st

MEI Pharma To Present At Wedbush PacGrow Healthcare Conference

MEI Pharma To Present At Wedbush PacGrow Healthcare Conference

Live Webcast from New York on August 11th

MEI Pharma To Present At Cantor Fitzgerald Healthcare Conference

MEI Pharma To Present At Cantor Fitzgerald Healthcare Conference

Live Webcast from New York on July 8th

MEI Pharma Reports Updated Results From Phase II Study Of Pracinostat And Azacitidine In Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

MEI Pharma Reports Updated Results From Phase II Study Of Pracinostat And Azacitidine In Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Clinical Responses Continue to Improve; Median Overall Survival Not Yet Reached

MEI Pharma To Present At Bank Of America Merrill Lynch Health Care Conference

MEI Pharma To Present At Bank Of America Merrill Lynch Health Care Conference

Live Webcast from Las Vegas on May 13th

MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity In Combination With Tyrosine-Kinase Inhibitor In Pre-Clinical Studies

MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity In Combination With Tyrosine-Kinase Inhibitor In Pre-Clinical Studies

New Studies Identify Molecular Target, Mitochondria-Specific Effects of ME-344; Results from First-in-Human Clinical Study Published in Cancer

MEI Pharma To Present At Needham Healthcare Conference

MEI Pharma To Present At Needham Healthcare Conference

Live Webcast from New York on April 15th

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

Shares of MEI Pharma (MEIP) were up in late morning trading Tuesday as investors swooped into the stock following its significant decline on Monday.

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

Shares of MEI Pharma (MEIP) plunged to a one-year low on Monday after the company announced its cancer drug Pracinostat failed to meet its main goal in a mid-stage trial.

MEI Pharma To Present At Cowen And Company Health Care Conference

MEI Pharma To Present At Cowen And Company Health Care Conference

Live Webcast from Boston on March 4th

First Week Of April 17th Options Trading For MEI Pharma (MEIP)

First Week Of April 17th Options Trading For MEI Pharma (MEIP)

Investors in MEI Pharma Inc saw new options become available this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MEIP options chain for the new April 17th contracts and identified one put and one call contract of particular interest.

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

Keep these under-$10 biotech stocks on your breakout trading radar.